GlassScriptPhysician profile
Richard William Johnson
NPI 1851399489
$1,451.92
in general payments reported to CMS, 2019-2025
28 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $202 · 2021: $321 · 2022: $243 · 2023: $94.03 · 2024: $231 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $188.17 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $177.87 | 2020-2025 | |
| Amgen INC. | $107.37 | 2019-2025 | Prolia, Evenity, Repatha |
| Abbvie INC. | $102.75 | 2020-2025 | |
| Abbott Laboratories | $94.06 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $87.98 | 2020-2025 | Gardasil 9, Enflonsia, Capvaxive |
| Novo Nordisk INC | $84.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $80.84 | 2020-2023 | Xarelto |
| Glaxosmithkline, LLC. | $69.70 | 2021-2025 | Arexvy, Shingrix |
| Currax Pharmaceuticals LLC | $63.74 | 2022-2025 | Contrave, Onzetra Xsail |
| Sanofi Pasteur INC. | $54.43 | 2019-2021 | |
| Apria Healthcare LLC | $44.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.79 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $33.03 | 2021-2024 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $28.06 | 2022-2024 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.81 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $20.07 | 2023 | Dexcom G6 Transmitter |
| Medtronic USA, INC. | $17.62 | 2019 | |
| Seqirus USA INC | $17.30 | 2025 | Flucelvax, Fluad |
| Astellas Pharma US INC | $16.15 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.96 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.03 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.76 | 2021 | |
| Eisai INC. | $12.97 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.69 | 2023 | |
| Collegium Pharmaceutical, INC. | $12.50 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.06 | 2021 | |
| Mylan Specialty L.P. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.